Oral

[O2-5] Hepadnavirus3

Mon. Nov 14, 2022 3:20 PM - 4:35 PM Room 5 (Conference Room 109)

Chair:Hideki Aizaki(National Institute of Infectious Diseases), Kenta Shimizu(Department of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University)

+Add all to schedule

3:20 PM - 3:35 PM

[O2-5-7] Spatiotemporal analysis of HBV entry dynamics

*Takara NISHIYAMA¹, Masashi IWAMOTO², Koichi WATASHI³, Shingo IWAMI¹ (1. Nagoya University, 2. Rockefeller University, 3. National Institute of Infectious Diseases)

3:35 PM - 3:50 PM

[O2-5-8] CLEC1B is a novel host factor that facilitates hepatitis B virus infection

*Tsubasa Munakata¹, Michinori Kohara¹ (1. Tokyo Metropolitan Institute of Medical Science)

3:50 PM - 4:05 PM

[O2-5-9] Development of recombinant hepatitis E virus harboring the luminescent tag HiBiT and its application in drug screening

*Shigeo Nagashima¹, Putu Prathiwi Primadharsini¹, Takashi Nishiyama², Masaharu Takahashi¹, Kazumoto Murata¹, Hiroaki Okamoto¹ (1. Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, 2. Laboratory for Drug Target Research, Bioscience and Biotechnology, Faculty of Agriculture, Shinshu University)

4:05 PM - 4:20 PM

[O2-5-10] Analysis of ritonavir inhibition target in hepatitis E virus life cycle and the efficacy of its combination with ribavirin in cultured cells

*Putu Prathiwi Primadharsini¹, Shigeo Nagashima¹, Masaharu Takahashi¹, Kazumoto Murata¹, Hiroaki Okamoto¹ (1. Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine)

4:20 PM - 4:35 PM

[O2-5-11] Mongolia gerbils are broadly susceptible to hepatitis E virus

*Tiancheng Li¹, Wenjing Zhang¹, Yasushi Ami¹, Yuriko Suzaki¹, Yen Hai Doan¹, Masamichi Muramatsu¹ (1. National Institute of Infectious Diseases)

Session information